J S Economou Selected Research

Melanoma (Melanoma, Malignant)

12/2001	CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
3/2001	Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
4/2000	Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J S Economou Research Topics

Disease

6	Neoplasms (Cancer) 12/2001 - 01/2000
4	Hepatocellular Carcinoma (Hepatoma) 12/2001 - 11/2000
3	Melanoma (Melanoma, Malignant) 12/2001 - 04/2000
1	Lung Neoplasms (Lung Cancer) 01/2000
1	Experimental Melanoma 01/2000

Drug/Important Bio-Agent (IBA)

4	AntigensIBA 12/2001 - 01/2000
3	Peptides (Polypeptides)IBA 04/2001 - 01/2000
2	alpha-Fetoproteins (alpha-Fetoprotein)IBA 12/2001 - 11/2000
2	EpitopesIBA 12/2001 - 04/2001
1	VaccinesIBA 12/2001
1	EnzymesIBA 04/2001
1	HLA-A*02:01 antigenIBA 04/2001
1	Cisplatin (Platino)FDA LinkGeneric 03/2001
1	Fas Ligand Protein (Fas Ligand)IBA 03/2001
1	Pharmaceutical PreparationsIBA 03/2001
1	CytokinesIBA 11/2000
1	Interleukin-12 (IL 12)IBA 11/2000
1	Factor VIII (Coagulation Factor VIII)IBA 11/2000
1	MART-1 AntigenIBA 01/2000
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2000
1	InterleukinsIBA 01/2000
1	Interleukin-7 (Interleukin 7)IBA 01/2000
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2000
1	Cancer VaccinesIBA 01/2000

Therapy/Procedure

6	Immunotherapy 12/2001 - 01/2000
1	Ligation 12/2001
1	Therapeutics 01/2000